Company Overview - Tectonic Therapeutic, Inc. is a clinical-stage biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of G-protein coupled receptors (GPCRs) [4] - The company leverages its proprietary technology platform called GEODe™ (GPCRs Engineered for Optimal Discovery) to develop biologic medicines aimed at overcoming challenges in GPCR-targeted drug discovery [4] - Tectonic targets areas of significant unmet medical need, where therapeutic options are limited or nonexistent, to improve patient quality of life [4] Recent Developments - Tectonic has been added to the Russell 3000 Index following the conclusion of the 2025 Russell US Indexes annual reconstitution, effective after the open of US equity markets on June 30, 2025 [1] - Membership in the Russell 3000 Index results in automatic inclusion in either the large-cap Russell 1000® Index or small-cap Russell 2000® Index, along with the appropriate growth and value style indexes [2]

Core Points - Tectonic Therapeutic, Inc. is a clinical-stage biotechnology company focused on developing therapeutic proteins and antibodies targeting G-protein coupled receptors (GPCRs) [1][4] - Alise Reicin, MD, the President and CEO of Tectonic, will present at the Bank of America Securities 2025 Health Care Conference in Las Vegas from May 12-15, 2025 [1][2] - The company will also host one-on-one meetings for interested investors during the conference [2] Company Overview - Tectonic utilizes its proprietary technology platform, GEODe™, to enhance GPCR-targeted drug discovery and aims to develop biologic medicines for significant unmet medical needs [4] - The company is headquartered in Watertown, Massachusetts, and focuses on areas where therapeutic options are limited or non-existent, aiming to improve patient quality of life [4]